AU4907300A - Use of gabapentin in assays to identify gabab receptor modulators - Google Patents

Use of gabapentin in assays to identify gabab receptor modulators

Info

Publication number
AU4907300A
AU4907300A AU49073/00A AU4907300A AU4907300A AU 4907300 A AU4907300 A AU 4907300A AU 49073/00 A AU49073/00 A AU 49073/00A AU 4907300 A AU4907300 A AU 4907300A AU 4907300 A AU4907300 A AU 4907300A
Authority
AU
Australia
Prior art keywords
gabapentin
assays
identify
receptor modulators
gabab receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49073/00A
Inventor
Gordon Ng
Gary O'neil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of AU4907300A publication Critical patent/AU4907300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU49073/00A 1999-06-01 2000-05-30 Use of gabapentin in assays to identify gabab receptor modulators Abandoned AU4907300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13702599P 1999-06-01 1999-06-01
US60137025 1999-06-01
PCT/CA2000/000638 WO2000073788A1 (en) 1999-06-01 2000-05-30 Use of gabapentin in assays to identify gabab receptor modulators

Publications (1)

Publication Number Publication Date
AU4907300A true AU4907300A (en) 2000-12-18

Family

ID=22475482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49073/00A Abandoned AU4907300A (en) 1999-06-01 2000-05-30 Use of gabapentin in assays to identify gabab receptor modulators

Country Status (5)

Country Link
EP (1) EP1188056A1 (en)
JP (1) JP2003501052A (en)
AU (1) AU4907300A (en)
CA (1) CA2375196A1 (en)
WO (1) WO2000073788A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098779A2 (en) * 2000-06-19 2001-12-27 Merck Frosst Canada & Co. Methods of identifying gabab receptor subtype-specific agonists
FR2827045B1 (en) 2001-07-05 2007-08-10 Univ Pasteur METHODS AND COMPOSITIONS FOR THE SELECTION AND DEVELOPMENT OF NEW PHARMACOLOGICAL AGENTS OR NEW MEDICINAL PRODUCTS
AU2004272302A1 (en) * 2003-09-12 2005-03-24 Janssen Pharmaceutica N.V. Chimeric GABAb receptor
WO2009102569A2 (en) * 2008-02-01 2009-08-20 Chromocell Corporation Novel cell lines and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854002A (en) * 1996-12-17 1998-12-29 Rhone Poulenc, Inc. Method of identifying compounds that bind to the insect gaba receptor
WO1999040114A1 (en) * 1998-02-05 1999-08-12 Merck & Co., Inc. Novel gabab receptor dna sequences

Also Published As

Publication number Publication date
WO2000073788A1 (en) 2000-12-07
EP1188056A1 (en) 2002-03-20
CA2375196A1 (en) 2000-12-07
JP2003501052A (en) 2003-01-14

Similar Documents

Publication Publication Date Title
AU2001231154A1 (en) Peptidomimetic modulators of cell adhesion
AU1950999A (en) System for converting scrolling display to non-scrolling columnar display
AU5290500A (en) Billboard consumption measurement system
AU9203298A (en) Ready to use campfire
AU3769197A (en) Use of (meth)acrylic acid copolymers to increase the permeability of muc ous membranes
AU1407699A (en) Distributed architecture utility
AU7842000A (en) Led display
AU5675099A (en) Use of zeranol to modulate reproductive cycles
AU4595700A (en) Improvements relating to illuminated jewellery
AU4907300A (en) Use of gabapentin in assays to identify gabab receptor modulators
AU6932900A (en) Liquid crystal matrix add/drop system
AU2003229716A1 (en) Use of gabab receptor positive modulators in gastro-instestinal disorders
AU7065500A (en) Compounds useful to mimic peptide beta-strands
AU3490499A (en) Vision architecture to describe features of persons
AUPO731697A0 (en) Improvements relating to combined steel-aluminium structures
AU8351198A (en) Improvements relating to connection devices
AU3494199A (en) Transparent composition
AU2001261133A1 (en) Detection of antibodies to gangliosides
AUPO978397A0 (en) Improvements to signs
AU2103600A (en) Improvements in or relating to displacement assays
AU1158001A (en) Improvements relating to computer graphics
AUPN524795A0 (en) Improvements to signs
AU2002224236A1 (en) Improvements relating to signal mixers
AU1892999A (en) Improvements to testing
AUPO512897A0 (en) Improvements to mixing barrels

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase